Monitoring recommendations for GC treatment vary depending on the duration of treatment and dose intensity. Recommended baseline monitoring includes serum glucose, lipid profile, and bone mineral density. After treatment begins, blood pressure, weight gain, visual changes, shortness of breath, edema, and polydipsia (excessive thirst) also should be checked during each physician visit. Additionally, if chronic long-term treatment with steroids is used, bone mineral density should be monitored at least
Body weight: Less than or equal to 25 kg: mg IM once a month
Body weight: Greater than 25 kg to kg: mg IM once a month
Body weight: Greater than kg: 15 mg IM once a month
-Hormonal levels should be tested after 1 to 2 months of therapy and with each dose change to ensure adequate pituitary gonadotropin suppression.
-Once a dose that results in adequate hormonal suppression, it can often be maintained for the duration of therapy in most children; however, hormonal suppression should be verified as weight can increase significantly while on therapy.
Initial dose: 50 mcg/kg/day subcutaneously. If total downregulation is not achieved, the dose should be titrated upward by 10 mcg/kg/day. This dose will be considered the maintenance dose.
-The dosage should be adjusted for weight changes.
-Discontinuation of therapy be considered before age 11 for females and before age 12 for males.
Use: Treatment of children with central precocious puberty (CPP)
Use of budesonide should be discontinued if such reactions occur. Quick Guide Asthma Symptoms, Causes, and Medications From Tips to Better Manage Your Migraine Start Now What is the dosage for budesonide inhaler?